<DOC>
	<DOC>NCT02477332</DOC>
	<brief_summary>This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.</brief_summary>
	<brief_title>Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Diagnosis of chronic spontaneous urticaria for at least 6 months Diagnosis of chronic spontaneous urticaria refractory to standard of care at time of randomization Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria Evidence of parasitic infection Any other skin diseases than chronic spontaneous urticaria with chronic itching Previous treatment with omalizumab or QGE031 Contraindications to or hypersensitivity to fexofenadine, loratadine, cetirizine, or epinephrine History of anaphylactic shock History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study History of hypersensitivity to any of the study drugs or its components of similar chemical classes Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>QGE031</keyword>
	<keyword>omalizumab</keyword>
	<keyword>chronic</keyword>
	<keyword>spontaneous</keyword>
	<keyword>urticaria</keyword>
	<keyword>adults</keyword>
	<keyword>CSU</keyword>
</DOC>